Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone

← catalyst calendar

NCT07314346 · readout ≤ 12 d

Sponsored by Atea Pharmaceuticals, Inc. (industry) · AVIR — their whole pipeline →.

Phase

Phase 1

Status

Recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

32estimated

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2025-01-07

actual

When the study began enrolling

Primary completion

Aug 2026

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Aug 2026

estimated

The whole study's end, after follow-up

First posted

2026-01-02

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-16

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Healthy Volunteer Study

Interventions

Drug: Buprenorphine/Naloxone + BEM/RZR — also filed as BEM (AT-527)/RZR (AT-038)
Drug: Methadone +BEM/RZR — also filed as BEM (AT-527)/RZR (AT-038)

Primary outcomes

what the primary-completion date above is the date OF

Effect of BEM/RZR on PK of buprenorphine,norbuprenorphine and naloxone

measured Day -5 to Day 13

Effect of BEM/RZR on PK of buprenorphine,norbuprenorphine and naloxone

measured Day -5 to Day 13

Effect of BEM/RZR on PK of methadone

measured Day -5 to Day 13

Effect of BEM/RZR on PK of methadone

measured Day -5 to Day 13

Permalink · AVIR's whole pipeline · Catalyst calendar · Every registered study · What changed